Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents

Giovanna Damia, Luigi Imperatori, Miria Stefanini, Maurizio D'Inacai

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Nucleotide excision repair (NER) is one of the major DNA repair systems in mammalian cells, able to remove a broad spectrum of unrelated lesions. In this report the role of ERCC (excision repair cross-complementing) I, ERCC2, ERCC3, ERCC4 and ERCC6 genes in removing the lesions caused by alkylating agents with different structures and mechanisms of action has been studied using UV-sensitive DNA repair-deficient mutant CHO cell lines. We confirmed that ERCC1 and ERCC4 play a role in the repair of cis- diamminedichloroplatinum (DDP)- and Melphalan (L-PAM)-induced DNA damage, while a marginal role of ERCC2 and ERCC3 in the cellular response to DDP and L-PAM treatment has been observed. Treatment with methylating agents (DM and MNNG) showed a lack of a preferential cytotoxicity between the parental and the different NER-deficient cell lines, emphasizing the importance of other repair systems such as 3-methyledenine glycosylase and O6 alkylguanine-DNA- alkyl-transferase. ERCC1, ERCC2, ERCC3 and ERCC4, but not ERCC6 gene products seem to be involved in removing the lesions caused by Tallimustine and CC1065, minor groove alkylating agents that alkylate N3 adenine in a sequence-specific manner. ERCC6-deficient cells were as sensitive as the parental cell line to all the cytotoxic drugs tested, except DDP. These data emphasize the importance of the CHO mutant cell lines with specific defects in the DNA repair system for investigating the mechanism of action of different anti-cancer agents.

Original languageEnglish
Pages (from-to)779-783
Number of pages5
JournalInternational Journal of Cancer
Volume66
Issue number6
DOIs
Publication statusPublished - Jun 11 1996

Fingerprint

CHO Cells
DNA Repair
Melphalan
Cell Line
Alkylating Agents
Neoplasms
DNA Repair-Deficiency Disorders
Methylnitronitrosoguanidine
Adenine
Transferases
Cisplatin
Genes
DNA Damage
DNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. / Damia, Giovanna; Imperatori, Luigi; Stefanini, Miria; D'Inacai, Maurizio.

In: International Journal of Cancer, Vol. 66, No. 6, 11.06.1996, p. 779-783.

Research output: Contribution to journalArticle

@article{b885e04fb6614a8f85d5f5ba33368ad7,
title = "Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents",
abstract = "Nucleotide excision repair (NER) is one of the major DNA repair systems in mammalian cells, able to remove a broad spectrum of unrelated lesions. In this report the role of ERCC (excision repair cross-complementing) I, ERCC2, ERCC3, ERCC4 and ERCC6 genes in removing the lesions caused by alkylating agents with different structures and mechanisms of action has been studied using UV-sensitive DNA repair-deficient mutant CHO cell lines. We confirmed that ERCC1 and ERCC4 play a role in the repair of cis- diamminedichloroplatinum (DDP)- and Melphalan (L-PAM)-induced DNA damage, while a marginal role of ERCC2 and ERCC3 in the cellular response to DDP and L-PAM treatment has been observed. Treatment with methylating agents (DM and MNNG) showed a lack of a preferential cytotoxicity between the parental and the different NER-deficient cell lines, emphasizing the importance of other repair systems such as 3-methyledenine glycosylase and O6 alkylguanine-DNA- alkyl-transferase. ERCC1, ERCC2, ERCC3 and ERCC4, but not ERCC6 gene products seem to be involved in removing the lesions caused by Tallimustine and CC1065, minor groove alkylating agents that alkylate N3 adenine in a sequence-specific manner. ERCC6-deficient cells were as sensitive as the parental cell line to all the cytotoxic drugs tested, except DDP. These data emphasize the importance of the CHO mutant cell lines with specific defects in the DNA repair system for investigating the mechanism of action of different anti-cancer agents.",
author = "Giovanna Damia and Luigi Imperatori and Miria Stefanini and Maurizio D'Inacai",
year = "1996",
month = "6",
day = "11",
doi = "10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z",
language = "English",
volume = "66",
pages = "779--783",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents

AU - Damia, Giovanna

AU - Imperatori, Luigi

AU - Stefanini, Miria

AU - D'Inacai, Maurizio

PY - 1996/6/11

Y1 - 1996/6/11

N2 - Nucleotide excision repair (NER) is one of the major DNA repair systems in mammalian cells, able to remove a broad spectrum of unrelated lesions. In this report the role of ERCC (excision repair cross-complementing) I, ERCC2, ERCC3, ERCC4 and ERCC6 genes in removing the lesions caused by alkylating agents with different structures and mechanisms of action has been studied using UV-sensitive DNA repair-deficient mutant CHO cell lines. We confirmed that ERCC1 and ERCC4 play a role in the repair of cis- diamminedichloroplatinum (DDP)- and Melphalan (L-PAM)-induced DNA damage, while a marginal role of ERCC2 and ERCC3 in the cellular response to DDP and L-PAM treatment has been observed. Treatment with methylating agents (DM and MNNG) showed a lack of a preferential cytotoxicity between the parental and the different NER-deficient cell lines, emphasizing the importance of other repair systems such as 3-methyledenine glycosylase and O6 alkylguanine-DNA- alkyl-transferase. ERCC1, ERCC2, ERCC3 and ERCC4, but not ERCC6 gene products seem to be involved in removing the lesions caused by Tallimustine and CC1065, minor groove alkylating agents that alkylate N3 adenine in a sequence-specific manner. ERCC6-deficient cells were as sensitive as the parental cell line to all the cytotoxic drugs tested, except DDP. These data emphasize the importance of the CHO mutant cell lines with specific defects in the DNA repair system for investigating the mechanism of action of different anti-cancer agents.

AB - Nucleotide excision repair (NER) is one of the major DNA repair systems in mammalian cells, able to remove a broad spectrum of unrelated lesions. In this report the role of ERCC (excision repair cross-complementing) I, ERCC2, ERCC3, ERCC4 and ERCC6 genes in removing the lesions caused by alkylating agents with different structures and mechanisms of action has been studied using UV-sensitive DNA repair-deficient mutant CHO cell lines. We confirmed that ERCC1 and ERCC4 play a role in the repair of cis- diamminedichloroplatinum (DDP)- and Melphalan (L-PAM)-induced DNA damage, while a marginal role of ERCC2 and ERCC3 in the cellular response to DDP and L-PAM treatment has been observed. Treatment with methylating agents (DM and MNNG) showed a lack of a preferential cytotoxicity between the parental and the different NER-deficient cell lines, emphasizing the importance of other repair systems such as 3-methyledenine glycosylase and O6 alkylguanine-DNA- alkyl-transferase. ERCC1, ERCC2, ERCC3 and ERCC4, but not ERCC6 gene products seem to be involved in removing the lesions caused by Tallimustine and CC1065, minor groove alkylating agents that alkylate N3 adenine in a sequence-specific manner. ERCC6-deficient cells were as sensitive as the parental cell line to all the cytotoxic drugs tested, except DDP. These data emphasize the importance of the CHO mutant cell lines with specific defects in the DNA repair system for investigating the mechanism of action of different anti-cancer agents.

UR - http://www.scopus.com/inward/record.url?scp=0029890253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029890253&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z

DO - 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z

M3 - Article

VL - 66

SP - 779

EP - 783

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -